We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current LVZPF market cap is 1.06B. The company's latest EPS is CNY and P/E is N/A.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 9.28B | 10.4B | 11.93B | 12.48B | 12.28B |
| Operating Income | 5.88B | 6.72B | 7.67B | 8.02B | 7.81B |
| Net Income | 1.3B | 1.71B | 1.78B | 1.91B | 1.95B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 17.98B | 20.59B | 22.37B | 24.86B | 25.04B |
| Total Liabilities | 5.7B | 6.95B | 8.06B | 9.93B | 10.28B |
| Total Equity | 12.28B | 13.64B | 14.31B | 14.94B | 14.77B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 1.77B | 2.16B | 1.9B | 2.77B | 3.25B |
| Investing | -316.02M | -467.84M | -1.88B | -1.23B | -708.37M |
| Financing | -1.18B | -518.04M | -815.02M | -720.36M | -1.66B |
| Market Cap | 1.06B |
| Price to Earnings Ratio | N/A |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0 |
| Dividend Yield | - |
| Shares Outstanding | 309.83M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 7.19% |
| 52 Week High | 3.63 |
| 52 Week Low | 3.20 |
| Spread (Intraday) | 1 (26.53%) |
| Company Name | Livzon Pharmaceutical Group Inc (PK) |
| Address |
headquarters building zhuhai, guangdong 519090 |
| Website | https://www.livzon.com.cn |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
